English
Polski
Español
українська
Rh0(D) immunoglobulin (RhIG) is a blood product that contains anti-D immunoglobulins derived from human blood donors administered for the purpose of preventing RhD alloimmunization.
IndicationsTop
RhIG is most commonly administered to nonalloimmunized, RhD-negative women during pregnancy, following delivery, and at the time of any complications of pregnancy during which fetal-maternal blood exchange may occur. The dosage administered depends on a variety of factors, including timing in and after pregnancy, extent of fetal-maternal blood exchange, manufacturer recommendations, and jurisdictional guidelines.
Indications for RhIG administration outside of pregnancy include administration of RhD-positive platelets to an RhD-negative recipient, prevention of RhD alloimmunization, and treatment of immune thrombocytopenia (ITP).
